key: cord-0802170-nak0910f authors: Holt, Gregory E.; Batra, Mayank; Murthi, Mukunthan; Kambali, Shweta; Santos, Kayo; Bastidas, Maria Virginia Perez; Asif, Huda; Haddadi, Sara; Arias, Sixto; Mirsaeidi, Mehdi title: Lack of tocilizumab effect on mortality in COVID19 patients date: 2020-10-13 journal: Sci Rep DOI: 10.1038/s41598-020-74328-x sha: cb981ea9e540259b6aaf0e5ee8ad778761f11163 doc_id: 802170 cord_uid: nak0910f Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations. www.nature.com/scientificreports/ found patients with rising IL-6 levels greater than 4000 pg/mL perished despite receiving tocilizumab 6 . These IL-6 levels begin to reach those seen in cytokine release syndrome (CRS) following CAR T cell infusion where levels reach a median value of 8,309 pg/mL for grade 4 or 5 CRS 7 . The finding of an elevated cytokine level in disease does not prove causality regardless of the degree of correlation. However, rapid reversal of a clinical syndrome through use of cytokine specific blockade provides good data linking that cytokine to disease pathogenesis. Use of tocilizumab for CRS in patients treated with CAR T cells causes a dramatic improvement in disease usually within 48 h 8, 9 . To date, tocilizumab has not had the same dramatic effect on reversing COVID-19 pneumonia like it does in CRS from CAR-T cell infusion despite papers suggesting possible benefit when compared to historical controls [10] [11] [12] [13] [14] . Comparison of IL-6′s role in viral infections versus CRS after CAR-T cell infusion is informative. IL-6 is an important cytokine responsible for promoting anti-viral T cell responses, inhibiting viral replication and resolving inflammation to promote tissue repair 15 . However, mouse models of viral infections that artificially create supraphysiologic IL-6 levels (10,000 pg/mL) show viral persistence and increased immunopathology 16 . Immune stimulating agents in cancer, e.g. CAR T cells, are efficacious partly because they are impervious to negative immune regulation and allow unfettered immune reactions against tumor cells. Not surprisingly, the www.nature.com/scientificreports/ supraphysiologic IL-6 levels in CAR-T infusion both correlate with high tumor burdens 17 and appear to be directly responsible for disease as administration of tocilizumab dramatically improves clinical status usually within 48 h 3 . Our data and another retrospective cohort trial of matched patients showed tocilizumab had no effect on mortality 18 . There are several limitations to this retrospective cohort study including small sample size and retrospective cohort design. Tocilizumab was given based on clinical parameters and biomarkers assumed to indicate IL-6 mediated immunopathology. Although IL-6 is correlated with poorer outcomes, in COVID19 we do not know if, at what level or at what time point IL-6 leads to immunopathology. Tocilizumab may have failed to influence mortality because IL-6 may not be either responsible for, or the only cytokine involved in immunopathology. If IL-6 is responsible for CRS in COVID-19, it is unknown at what level or time point it changes from having antiviral properties to causing immunopathology. Use of tocilizumab in patients regardless of IL-6 levels may have diluted out patients for whom tocilizumab may have benefited obscuring its effect on mortality. Tocilizumab would not help patients who did not produce pathologic IL-6 levels but could be detrimental if lower IL-6 levels were necessary to fight the viral infection 15 . We believe the need to "do something" has superseded the need to evaluate disease to apply clinical trials based on data. We argue that evaluation of immune parameters in COVID19 patients need to first be studied to ensure that IL-6 is involved in immunopathology and second to determine at what level or time point in the clinical course of infection, IL-6 produces immunopathology. Serial measurements of key cytokines in COVID19 may characterize IL-6 and additional cytokine levels to correlate with clinical outcomes, before administration of tocilizumab. After measuring the levels of cytokines in the clinical course of a COVID19 infection, trials should be attempted to apply immune modulating therapy to patients for whom the immune system is causing disease via dysregulation. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study Managing cytokine release syndrome associated with novel T cell-engaging therapies Interleukin-6 as prognosticator in patients with COVID-19 Pathological findings of COVID-19 associated with acute respiratory distress syndrome Tocilizumab treatment in COVID-19: A single center experience Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Forest plot showing the variables used in the multivariate model among COVID19 subjects Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia Chimeric antigen receptor-modified T cells for acute lymphoid leukemia Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE) Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients The role of interleukin 6 during viral infections. Front Microbiol TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study The authors would like to thank the physicians and nurses of the COVID-19 units of University of Miami and all of the patients for their participation. The authors declare no competing interests. Correspondence and requests for materials should be addressed to M.M.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.